This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

AboutAboutAbout ATTR-CMMOD/MOAStudy DesignDosingEfficacy & SafetyAccess & SupportAccess & SupportAccess & Patient SupportEventsMaterialsVideos
Prescribing InformationPatient InformationIndication Patient Site
VYNDAMAX® (tafamidis) for ATTR-CM–a convenient single-capsule, once-daily dose A single VYNDAMAX 61-mg capsule is bioequivalent* to VYNDAQEL® (tafamidis meglumine) 80 mg (four 20-mg capsules) and is not interchangeable on a per-mg basis1 Prescribe VYNDAMAX once-daily

Can be taken with or without food

The capsule should be swallowed whole and not crushed or cut
If a dose is missed, instruct patients to take the dose as soon as remembered or to skip the missed dose and take the next dose at the regularly scheduled time

A single VYNDAMAX 61-mg capsule is bioequivalent* to VYNDAQEL® (tafamidis meglumine) 80 mg (four 20-mg capsules) and is not interchangeable on a per-mg basis1

As determined by the predefined 90% confidence interval criteria of 80%-125% bioequivalence limits for tafamidis area under curve (AUC) and peak plasma concentration (Cmax) after repeated oral daily dosing for 7 days.1ATTR-CM=transthyretin amyloid cardiomyopathy. Next: Primary analysis  Continue Loading
Reference: Lockwood PA, Le VH, O’Gorman MT, et al. The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 × 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev. 2020; 9(7):849-854.
VYNDAMAX® AND VYNDAQEL® are registered trademarks of Pfizer Inc.
A selective stabilizer of TTR

Explore the mechanism of action

 Explore Loading Resources on dosing and more Explore resources Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2023 Pfizer Inc. All rights reserved.

PP-VDM-USA-1226
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-VDM-USA-0908
INDICATION AND LIMITATIONS OF USEVYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Please see Full Prescribing Information including Patient Information.
Important Safety Information

Adverse Reactions

In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

Specific Populations​​​​​​​

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.

Indication VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Please see Full Prescribing Information including Patient Information.